Biogazelle
Accelerating the understanding of the transcriptome through excellence in science and technology.
Launch date
Market cap
-
Enterprise valuation
CAD12—18m (Dealroom.co estimates Sep 2014.)
Company register number 0890.803.953
Ghent East Flanders (HQ)
Financials
Estimates*
| EUR | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Revenues | 2.8m | - | - | - | - | - | - |
| % growth | 5 % | - | - | - | - | - | - |
| EBITDA | (<1m) | (<1m) | 3.9m | (<1m) | - | - | - |
| % EBITDA margin | (3 %) | - | - | - | - | - | - |
| Profit | (<1m) | (<1m) | 3.6m | (<1m) | (2.6m) | (1.4m) | (<1m) |
| % profit margin | (13 %) | - | - | - | - | - | - |
| R&D budget | 1.0m | <1m | 7.0m | - | - | - | - |
| R&D % of revenue | 36 % | - | - | - | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Spinout | ||
€2.0m | Series B | ||
* | N/A | Acquisition | |
| Total Funding | CAD3.0m | ||
Related Content
Recent News about Biogazelle
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.